BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), provides an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024.
Following the submission of its application in early September, DIAGNOS has engaged in ongoing communication with Health Canada, providing timely responses to all regulatory requests. After more than 11 proactive inquiries regarding the application’s status, we are pleased to announce that Health Canada has confirmed that the application is now under “active processing”, having progressed from a previous backlog.
“We remain steadfast to complying with all regulatory requirements and ensuring that Health Canada has all the necessary information to support the review of our CARA System application,” said André Larente, CEO of Diagnos Inc. “We appreciate the continued collaboration with Health Canada and are optimistic about the future progress of our application.”
Diagnos Inc. is dedicated to advancing its mission of providing cutting-edge medical diagnostic solutions, and the CARA System is a key part of the company’s growth strategy.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca
- Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak - July 2, 2025
- Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private Placement - July 2, 2025
- Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to a Convertible Loan Agreement - July 2, 2025
